Stratagene Corp. (NASDAQ STGN) on Wednesday said it intends to appeal the decision of a federal court in Texas in favor of Invitrogen Corp. (NASDAQ IVGN), on a patent lawsuit and that it will challenge the validity of the patent.

On July 25, 2006, the jury had determined that Invitrogen's 4,981,797 patent is valid and that Stratagene infringed that patent by making and selling its competent E. coli cell products, the company said in a statement.

The judge ruled that Stratagene must pay Invitrogen's attorney's fees, in an amount to be determined by the court and awarded Invitrogen $16.2 million in damages plus pre-judgment interest, Stratagene added.